Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,644 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.
Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, Levy M, Lodato RF, Ismail PM, Reese A, Schaumberg JP, Malik R, Dellinger RP; TLF LF-0801 Investigator Group. Guntupalli K, et al. Among authors: malik r. Crit Care Med. 2013 Mar;41(3):706-16. doi: 10.1097/CCM.0b013e3182741551. Crit Care Med. 2013. PMID: 23425819 Clinical Trial.
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Digumarti R, Wang Y, Raman G, Doval DC, Advani SH, Julka PK, Parikh PM, Patil S, Nag S, Madhavan J, Bapna A, Ranade AA, Varadhachary A, Malik R. Digumarti R, et al. Among authors: malik r. J Thorac Oncol. 2011 Jun;6(6):1098-103. doi: 10.1097/JTO.0b013e3182156250. J Thorac Oncol. 2011. PMID: 21532506 Free article. Clinical Trial.
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators. Ramalingam S, et al. Among authors: malik r. Ann Oncol. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19. Ann Oncol. 2013. PMID: 24050956 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R. Parikh PM, et al. Among authors: malik r. J Clin Oncol. 2011 Nov 1;29(31):4129-36. doi: 10.1200/JCO.2010.34.4127. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969509 Clinical Trial.
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R, Anderson I, Medgyasszay B, García-Campelo MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Sanchez-Hernandez A, Pritchett Y, Morris SR, Malik RK, Csőszi T. Ferrarotto R, et al. Among authors: malik rk. Cancer Med. 2021 Sep;10(17):5748-5756. doi: 10.1002/cam4.4089. Epub 2021 Aug 18. Cancer Med. 2021. PMID: 34405547 Free PMC article. Clinical Trial.
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA. Riess JW, et al. Among authors: malik r. Immunopharmacol Immunotoxicol. 2014 Apr;36(2):182-6. doi: 10.3109/08923973.2013.864671. Epub 2014 Feb 5. Immunopharmacol Immunotoxicol. 2014. PMID: 24494587 Free PMC article.
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH; G1T28-02 Study Group. Weiss JM, et al. Among authors: malik rk. Ann Oncol. 2019 Oct 1;30(10):1613-1621. doi: 10.1093/annonc/mdz278. Ann Oncol. 2019. PMID: 31504118 Free PMC article. Clinical Trial.
2,644 results